FYB1-targeted modulation of CAPG promotes AML progression
In this study, through analysis of large databases and both in vivo and in vitro experiments, we assessed the expression and role of FYB1 in AML and the relationship of FYB with patient prognosis. Downstream targets of the FYB1 gene were analyzed by RNA-seq. Database mining and in vitro experiments were used to further clarify the effect of the downstream target gelsolin-like actin-capping protein (CAPG) on AML cells and its relationship with patient prognosis. FYB1 expression was significantly higher in AML tissue and corresponded with a poor prognosis. FYB1 knockdown inhibited AML cell proliferation, promoted cell apopto...
Source: Molecular and Cellular Biochemistry - May 3, 2024 Category: Biochemistry Authors: Wenyuan Liu Hongli Yin Zhiwei Xie Fang Fang Jinhua Chu Linhai Yang Lingling Huang Songji Tu Huaju Cai Zhengyu Wu Anbang Wei Chengzhu Liu Yi Hong Xiaotong Tian Yan Cheng Jian Pan Ningling Wang Kunlong Zhang Source Type: research
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency
In this study, we established Cas9+ mouse models of t(8;21) AML with intact or deficient Tpr53 (a mouse homolog of TP53) using a retrovirus-mediated gene transfer and transplantation system. Trp53 deficiency accelerates the in vivo development of AML driven by RUNX1-ETO9a, a short isoform of RUNX1-ETO with strong leukemogenic potential. Trp53 deficiency also confers resistance to genetic depletion of RUNX1 and a TP53-activating drug in t(8;21) AML. However, Trp53-deficient t(8;21) AML cells were still sensitive to several drugs such as dexamethasone. Cas9+ RUNX1-ETO9a cells with/without Trp53 deficiency can produce AML in ...
Source: International Journal of Hematology - May 3, 2024 Category: Hematology Authors: Wenyu Zhang Jingmei Li Keita Yamamoto Susumu Goyama Source Type: research
FYB1-targeted modulation of CAPG promotes AML progression
In this study, through analysis of large databases and both in vivo and in vitro experiments, we assessed the expression and role of FYB1 in AML and the relationship of FYB with patient prognosis. Downstream targets of the FYB1 gene were analyzed by RNA-seq. Database mining and in vitro experiments were used to further clarify the effect of the downstream target gelsolin-like actin-capping protein (CAPG) on AML cells and its relationship with patient prognosis. FYB1 expression was significantly higher in AML tissue and corresponded with a poor prognosis. FYB1 knockdown inhibited AML cell proliferation, promoted cell apopto...
Source: Molecular and Cellular Biochemistry - May 3, 2024 Category: Biochemistry Authors: Wenyuan Liu Hongli Yin Zhiwei Xie Fang Fang Jinhua Chu Linhai Yang Lingling Huang Songji Tu Huaju Cai Zhengyu Wu Anbang Wei Chengzhu Liu Yi Hong Xiaotong Tian Yan Cheng Jian Pan Ningling Wang Kunlong Zhang Source Type: research
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency
In this study, we established Cas9+ mouse models of t(8;21) AML with intact or deficient Tpr53 (a mouse homolog of TP53) using a retrovirus-mediated gene transfer and transplantation system. Trp53 deficiency accelerates the in vivo development of AML driven by RUNX1-ETO9a, a short isoform of RUNX1-ETO with strong leukemogenic potential. Trp53 deficiency also confers resistance to genetic depletion of RUNX1 and a TP53-activating drug in t(8;21) AML. However, Trp53-deficient t(8;21) AML cells were still sensitive to several drugs such as dexamethasone. Cas9+ RUNX1-ETO9a cells with/without Trp53 deficiency can produce AML in ...
Source: International Journal of Hematology - May 3, 2024 Category: Hematology Authors: Wenyu Zhang Jingmei Li Keita Yamamoto Susumu Goyama Source Type: research
FYB1-targeted modulation of CAPG promotes AML progression
In this study, through analysis of large databases and both in vivo and in vitro experiments, we assessed the expression and role of FYB1 in AML and the relationship of FYB with patient prognosis. Downstream targets of the FYB1 gene were analyzed by RNA-seq. Database mining and in vitro experiments were used to further clarify the effect of the downstream target gelsolin-like actin-capping protein (CAPG) on AML cells and its relationship with patient prognosis. FYB1 expression was significantly higher in AML tissue and corresponded with a poor prognosis. FYB1 knockdown inhibited AML cell proliferation, promoted cell apopto...
Source: Molecular and Cellular Biochemistry - May 3, 2024 Category: Biochemistry Authors: Wenyuan Liu Hongli Yin Zhiwei Xie Fang Fang Jinhua Chu Linhai Yang Lingling Huang Songji Tu Huaju Cai Zhengyu Wu Anbang Wei Chengzhu Liu Yi Hong Xiaotong Tian Yan Cheng Jian Pan Ningling Wang Kunlong Zhang Source Type: research
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency
In this study, we established Cas9+ mouse models of t(8;21) AML with intact or deficient Tpr53 (a mouse homolog of TP53) using a retrovirus-mediated gene transfer and transplantation system. Trp53 deficiency accelerates the in vivo development of AML driven by RUNX1-ETO9a, a short isoform of RUNX1-ETO with strong leukemogenic potential. Trp53 deficiency also confers resistance to genetic depletion of RUNX1 and a TP53-activating drug in t(8;21) AML. However, Trp53-deficient t(8;21) AML cells were still sensitive to several drugs such as dexamethasone. Cas9+ RUNX1-ETO9a cells with/without Trp53 deficiency can produce AML in ...
Source: International Journal of Hematology - May 3, 2024 Category: Hematology Authors: Wenyu Zhang Jingmei Li Keita Yamamoto Susumu Goyama Source Type: research
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 3, 2024 Category: Hematology Authors: Kellie J. Archer, Han Fu, Krzysztof Mr ózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold and Ann-Kathrin Eisfeld Tags: Correspondence Source Type: research
miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers
Conclusions: miR-133a and miR-135a may play an antioncogenic role in pediatric AML through the ATRA-miRNA133a/135a-CDX2 pathway. They hold promise as potentially favorable prognostic indicators and novel therapeutic targets for pediatric AML.PMID:38693824 | DOI:10.1177/15330338241248576 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - May 2, 2024 Category: Cancer & Oncology Authors: Yu-Cai Cheng Zhong Fan Cong Liang Chun-Jin Peng Yu Li Li-Na Wang Jie-Si Luo Xiao-Li Zhang Yong Liu Li-Dan Zhang Source Type: research
Cytarabine-induced peripheral neuropathy in a young patient with acute myeloid leukemia: a case report
CONCLUSION: Although rare, even a conventional dosage of cytarabine can cause peripheral neuropathy, and routine neuromuscular examinations can help in the early diagnosis and intervention to limit further progression and reverse the course of the disease.PMID:38694396 | PMC:PMC11060256 | DOI:10.1097/MS9.0000000000001937 (Source: Annals of Medicine)
Source: Annals of Medicine - May 2, 2024 Category: Internal Medicine Authors: Kshitiz Karki Sugat Adhikari Suraj Shrestha Jenish Bhandari Bidisha Baral Aastha Baral Source Type: research
Acute promyelocytic leukemia with additional chromosome abnormalities in a patient positive for HIV: A case report and literature review
This report describes a 49-year-old female patient with HIV who was diagnosed with high-risk APL with a new CK translocation and presents a literature review. At diagnosis, the patient presented with typical t(15;17)(q24;q21) with additional abnormalities, including add(5)(q15), add(5)(q31), add(7)(q11.2) and add(12) (p13). The results of acute myeloid leukemia mutation analysis suggested positivity for calreticulin and lysine methyltransferase 2C genes. The patient received all-trans retinoic acid combined with arsenic trioxide and chemotherapy, with morphologically complete remission after the first cycle of chemotherapy...
Source: Oncology Letters - May 2, 2024 Category: Cancer & Oncology Authors: Xiao-Lan Li Min Li Ling-Zhi Wang Juan Tian Zi-Wei Shi Kui Song Source Type: research
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print.ABSTRACTPatients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagnosed AML who received intensive treatment (IT) or low-intensity treatment (LIT). Of these patients, 197 experienced subsequent rAML. Data was available for 164 patients, with a median time from CR/CRi to relapse of 6.5 months. Thirty-five of the 164 patients (21%) experienced relapse afte...
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Alex Bataller Hagop Kantarjian Alexandre Bazinet Tapan Kadia Naval Daver Courtney D DiNardo Gautam Borthakur Sanam Loghavi Keyur Patel Guilin Tang Koji Sasaki Nicholas J Short Musa Yilmaz Ghayas C Issa Yesid Alvarado Guillermo Montalban-Bravo Abhishek Mai Source Type: research
miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers
Conclusions: miR-133a and miR-135a may play an antioncogenic role in pediatric AML through the ATRA-miRNA133a/135a-CDX2 pathway. They hold promise as potentially favorable prognostic indicators and novel therapeutic targets for pediatric AML.PMID:38693824 | DOI:10.1177/15330338241248576 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - May 2, 2024 Category: Cancer & Oncology Authors: Yu-Cai Cheng Zhong Fan Cong Liang Chun-Jin Peng Yu Li Li-Na Wang Jie-Si Luo Xiao-Li Zhang Yong Liu Li-Dan Zhang Source Type: research
Cytarabine-induced peripheral neuropathy in a young patient with acute myeloid leukemia: a case report
CONCLUSION: Although rare, even a conventional dosage of cytarabine can cause peripheral neuropathy, and routine neuromuscular examinations can help in the early diagnosis and intervention to limit further progression and reverse the course of the disease.PMID:38694396 | PMC:PMC11060256 | DOI:10.1097/MS9.0000000000001937 (Source: Annals of Medicine)
Source: Annals of Medicine - May 2, 2024 Category: Internal Medicine Authors: Kshitiz Karki Sugat Adhikari Suraj Shrestha Jenish Bhandari Bidisha Baral Aastha Baral Source Type: research
Acute promyelocytic leukemia with additional chromosome abnormalities in a patient positive for HIV: A case report and literature review
This report describes a 49-year-old female patient with HIV who was diagnosed with high-risk APL with a new CK translocation and presents a literature review. At diagnosis, the patient presented with typical t(15;17)(q24;q21) with additional abnormalities, including add(5)(q15), add(5)(q31), add(7)(q11.2) and add(12) (p13). The results of acute myeloid leukemia mutation analysis suggested positivity for calreticulin and lysine methyltransferase 2C genes. The patient received all-trans retinoic acid combined with arsenic trioxide and chemotherapy, with morphologically complete remission after the first cycle of chemotherapy...
Source: Oncology Letters - May 2, 2024 Category: Cancer & Oncology Authors: Xiao-Lan Li Min Li Ling-Zhi Wang Juan Tian Zi-Wei Shi Kui Song Source Type: research
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print.ABSTRACTPatients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagnosed AML who received intensive treatment (IT) or low-intensity treatment (LIT). Of these patients, 197 experienced subsequent rAML. Data was available for 164 patients, with a median time from CR/CRi to relapse of 6.5 months. Thirty-five of the 164 patients (21%) experienced relapse afte...
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Alex Bataller Hagop Kantarjian Alexandre Bazinet Tapan Kadia Naval Daver Courtney D DiNardo Gautam Borthakur Sanam Loghavi Keyur Patel Guilin Tang Koji Sasaki Nicholas J Short Musa Yilmaz Ghayas C Issa Yesid Alvarado Guillermo Montalban-Bravo Abhishek Mai Source Type: research
